Evidence map›Paper›PMID 35247197›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2022

Distinct power of bone marrow microRNA signatures and tumor suppressor genes for early detection of acute leukemia.

Fatemeh Memari, Vahid Tavakolpour, Nasrin Mohajeri, Behzad Poopak, Parviz Fallah, Effat Alizadeh, Fatemeh Kouhkan, Nosratollah Zarghami

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Fatemeh MemariDepartment of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Vahid TavakolpourDepartment of Stem Cells and Regenerative Medicine, Faculty of Medicine Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
Nasrin MohajeriDepartment of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Behzad PoopakMedical Science Branch, Islamic Azad University of Tehran, Tehran, Iran.
Parviz FallahCheckup Clinical and Specialty Laboratory, Karaj, Iran.
Effat AlizadehDepartment of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Fatemeh KouhkanStem Cell Technology Research Center, P.O. Box: 15856-36473, 15856-36473, Tehran, Iran. f.kouhkan@stemcellstech.com.
Nosratollah ZarghamiDepartment of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. Zarghami@tbzmed.ac.ir.ORCID http://orcid.org/0000-0002-4236-4537
Tabriz University of Medical Sciences · IRStem Cell Technology Research Center · IRIslamic Azad University Medical Branch of Tehran · IR

Funding

Tabriz University of Medical Sciences IR.TBZMED.VCR.REC.1397.019
6 · The paper itself

Abstract

backgroundAcute leukemia involving lymphocytic and myeloid cells is cancer with a high mortality rate. Swift and timely diagnosis might be a potential approach to improving patient prognosis and survival. The microRNA (miRNA) signatures are emerging nowadays for their promising diagnostic potential. MiRNA levels from bone marrow can be used as prognostic biomarkers.

methodsThe current study was designed to evaluate if the microRNAs and tumor suppressor genes (TSGs) profiling of hematopoietic bone marrow could help in acute leukemia early detection. Also, we assessed the DNA methyltransferase 3A (DNMT3A) expression and its possible epigenetic effects on miRNAs plus TSGs expression levels. The expression levels of ten miRNAs and four TSGs involved in acute lymphocytic leukemia (ALL) as well as acute myeloid leukemia (AML) were quantified in 43 and 40 bone marrow samples of ALL and AML patients in comparison with cancer-free subjects via real-time quantitative PCR (RT-qPCR). The receiver-operating-characteristic (ROC) analysis of miRNAs was performed in the study groups. Further, the correlation between the DNMT3A and TSGs was calculated.

resultsSignificant differences were detected in the bone marrow expression of miRNAs and TSGs (P < 0.05) between acute leukemia patients and healthy group. ROC analysis confirmed the ability of miR-30a, miR-101, miR-132, miR-129, miR-124, and miR-143 to discriminate both ALL and AML patients with an area under the ROC curve of ≥ 0.80 (P < 0.001) and high accuracy. The correlation between DNMT3A and P15/P16 TSGs revealed that DNMT3A plays a vital role in epigenetic control of TSGs expression. Our findings indicated that the downregulation of bone marrow miRNAs and TSGs was accompanied by acute leukemia development.

conclusionsThe authors conclude that this study could contribute to introducing useful biomarkers for acute leukemia diagnosis.

Indexed as

Leukemia, Myeloid, AcuteMicroRNAsPrecursor Cell Lymphoblastic Leukemia-LymphomaBiomarkers, TumorBone MarrowEarly Detection of CancerGenes, Tumor SuppressorHumansPrognosisBiomarkers, TumorMicroRNAsMirn129 microRNA, humanAcute Lymphocytic Leukemia (ALL)Acute Myeloid Leukemia (AML)DNMT3AEpigeneticmiRNAs

Identifiers

PMID35247197
OpenAlexW4220740902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.